google-site-verification: google28f501b00d980d5f.html Breaking €1 billion for the first time, Ceva Santé Animale consolidates its position as the leading French player in the global animal health market - Vetpol Community

Announcement

Collapse
No announcement yet.

Breaking €1 billion for the first time, Ceva Santé Animale consolidates its position as the leading French player in the global animal health market

Collapse
X
Collapse

  • Breaking €1 billion for the first time, Ceva Santé Animale consolidates its position as the leading French player in the global animal health market

    Click image for larger version

Name:	campus.png
Views:	2
Size:	77.2 KB
ID:	45587
    New Building Project at the Ceva Sogeval Campus

    2017 will go down in history as the year Ceva Santé Animale (Ceva) achieved growth of 20% and broke the billion euro barrier for the first time with sales of €1.1 billion. This performance consolidates its position as the 6th largest animal health company and leading French multinational in the sector.

    A year of growth based on successful integrations
    In 2017, Ceva grew its business by 20%, achieving turnover of €1.1 billion. Performance was strong across all geographical regions. The global sales are split as follows Europe - 34%, Africa-Middle East-Eastern Europe-Turkey - 19%, North America-Pacific – 16%, Latin America – 15% and Asia – 13%.

    In terms of product portfolios, the Swine business recorded the biggest increase (up 66%, representing 16% of sales) due mainly to the acquisition of 4 ex-Merial vaccines. Ruminants sales were up 40%, (20% of turnover) driven by the acquisition of Brazilian firms Hertape and Inova. Companion Animals sales grew 12%, (29% of turnover), with Poultry up 8%, (35% of turnover).

    Ceva Chairman and CEO, Dr. Marc Prikazsky delighted with these latest results said: “Our strong growth can be explained largely through our most recent acquisitions, Hertape and Inova in Brazil, but equally the purchase of a number of ex-Merial products and the acquisitions of Ebvac, China, Polchem in India and Biovac, France. However, our organic growth was also a driver, achieving an historic 9% increase (at constant scope and exchange rates). This success is due to the hard work of all our teams, in particular those in Libourne, for the smooth integration of these new companies, as well as the R&D, industrial and logistics teams for the development of such innovative new products as Feliscratch by Feliway®, Zeleris® and Smartvac®.”

    Ceva intends to maintain its strong dynamic through innovation and major global investment in its industrial sites
    Dr. Prikazsky adds: “In these times of rapid global change, we need to make the most of our agility to quickly integrate, from today, the new orientations of research in areas such as artificial intelligence, connected agriculture, robotisation, digitalisation, big data, etc. The challenge for the future will be how to integrate these new technologies into our business model. This is a challenge for the agricultural community as a whole, both in France and around the world. In all these areas, once again, Ceva wants to become a first-line reference.”

    Along the lines of its investment last year in Applifarm, a Big Data platform for the ruminants sector, Ceva is looking to develop new services, particularly in hatcheries around its vector-vaccine and in-ovo vaccination equipment developed by its French subsidiary, Ecat-iD.2018 will also see the realisation of three major projects in France under the “Factory of the Future” banner:
    • Construction in Laval, Mayenne of a global centre of expertise in companion animals. Between 2014 and 2020 Ceva will have invested €25 million in the Ceva Sogeval Campus, with €7.5 million of that going towards the construction of an ultramodern 3600m2 campus – including a 1000m2 laboratory and Quality Control building (due to open in February 2018).
    • Construction of a 2000m2 building in Loudéac, Brittany. Ceva has invested €6.8 million in order to integrate a range of dermatological products for Companion animals. In addition to the Feliway® and Adaptil® ranges it will produce the Douxo® range for the European market, with the aim of becoming the world leader in topical dermatology products by 2020 (due to open in May 2018).
    • Construction of a 2600m2 industrial building in Libourne, Gironde. With an investment of €8.5 million the Group hopes to increase storage capacity for vaccines and, at the same time, improve its logistics (due to open in November 2018). This year, Ceva will also initiate a project to examine how to reorganise the entire Libourne site, which includes its head office, with the aim of improving the work environment and encouraging exchange between different services.
    To maintain its constant rhythm of growth, it is imperative that Ceva continues to invest in the future, in innovation, in new sectors like biotechnology and in R&D – particularly in relation to swine and poultry biology,” explains Marc Prikazsky.
    Attached Files
      Posting comments is disabled.

    Categories

    Collapse

    Article Tags

    Collapse

    Latest Articles

    Collapse

    • VMA Annual Awards: Advertising Campaign Award
      Kristina Kisbee

      The Veterinary Marketing Association (VMA) flagship Annual Awards take place on 15th March 2019 at the 5-star Royal Lancaster London hotel. As the premier veterinary marketing event of the year, the Awards provide a great opportunity for marketing professionals to showcase their skill and professionalism in marketing their products and services, says VMA Awards chair, Claire Edmunds.

      “There are 18 awards spanning all aspects of veterinary marketing, including the Young...
      Today, 04:05 PM
    • OnsiorTM (6 mg tablets) receives new indication to treat pain and inflammation in cats with chronic musculoskeletal disease
      Kristina Kisbee

      Elanco is delighted to announce Onsior (6 mg tablets) has been licensed for the treatment of pain and inflammation associated with chronic musculoskeletal disorders in cats.

      The new indication is in addition to its existing license for acute pain and inflammation.

      Vets now have another option when choosing the most suitable and effective treatment for cats with chronic musculoskeletal pain and can have confidence in the robust safety profile of Onsior 6 mg tablets
      ...
      Today, 04:03 PM
    • International equine welfare veterinarian Alex Atock publishes memoir of pathfinding organizational change to benefit “My Friend the Horse”
      Kristina Kisbee

      “My Friend, The Horse”, a new autobiography of international veterinarian Alex Atock, MRCVS, details 35 years of landmark equine health and welfare developments, such as:
      ● Changes in international equestrian sports while the author was head of the Veterinary Department of the Fédération Équestre Internationale (FEI), particularly related to inspection and medication of horses;
      ● Insight into equine care education in developing world while responsible for
      ...
      Today, 08:25 AM
    • Sick of gasping for breath - airway surgery could be considered for GI problems - WSAVA article
      Kristina Kisbee


      Everyone knows that brachycephalic dogs have a lot of health problems. Professor Nick Jeffery, editor-in-chief of the Journal of Small Animal Practice, our Official Scientific Journal, highlights a paper that suggests some of these may be linked...

      Many brachycephalic dogs have difficulties with breathing, but many also show frequent vomiting or regurgitation, or both. In this month’s JSAP, Dr Kaye and colleagues show evidence that airway and GI problems may be linked,
      ...
      Today, 08:11 AM
    • Grapiprant a breakthrough for osteoarthritic dogs?
      Kristina Kisbee

      Grapiprant is a new class of drug for treating ‘pain associated with mild to moderate osteoarthritis in dogs’. A balanced appraisal of this new drug is now available from Veterinary Prescriber in the form of a succinct online learning module. Anyone who does the module will:·
      • Understand the pharmacology of grapiprant.
      • Know the clinical evidence on the efficacy and safety of grapiprant.
      • Be aware of what is known about how grapiprant compares with NSAIDs.
      • Understand what is meant by
      ...
      Yesterday, 02:06 PM
    • Equissage Pulse announce results of scientifically proven research
      Kristina Kisbee

      Equissage Pulse are pleased to announce the results of scientifically proven research, recently published on the Journal of Equine Veterinary Science website, into the benefits that a 20-Minute Cycloidal Vibration has on Whole Horse Locomotion and Thoracolumbar Profiles.

      Carried out at The Kings Troop Royal Horse Artillery by Centaur Biomechanics, the independent blinded randomised controlled study delivers a verdict of the positive efficacy of cycloidal vibration therapy when...
      Yesterday, 12:53 PM
    Working...
    X